-+ 0.00%
-+ 0.00%
-+ 0.00%
Sellas’ GPS Vaccine Cuts Death Risk 41% in Phase 3 AML Trial
Share
Listen to the news
Sellas’ GPS Vaccine Cuts Death Risk 41% in Phase 3 AML Trial
  • Sellas Life Sciences announced its Phase 3 REGAL trial met its primary endpoint, with galinpepimut-S significantly improving overall survival versus best available treatment.
  • The cancer vaccine targeted acute myeloid leukemia patients in second or later remission who could not undergo stem cell transplantation.
  • Treatment was generally well tolerated, with no new safety signals identified.
  • FDA discussions will address an accelerated filing strategy, with preparations advancing for a Biologics License Application submission in the first half of 2027.
  • Topline results were announced November 17, 2026; detailed findings will be presented at a future major medical conference.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170700PRIMZONEFULLFEED9879189) on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending